

# Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation

Issued: December 2011

**NICE clinical guideline 135**

[guidance.nice.org.uk/cg135](http://guidance.nice.org.uk/cg135)

---

## Contents

Introduction.....	4
Person-centred care .....	5
1 Recommendations .....	6
Identifying patients who are potential donors.....	6
Patients who have capacity.....	6
Assessing best interests .....	7
Seeking consent to organ donation .....	7
Approach to those close to the patient.....	8
Discussions in all cases .....	9
Organisation of the identification, referral and consent processes .....	11
2 Notes on the scope of the guideline .....	14
3 Implementation .....	15
4 Research recommendations .....	16
4.1 Joining the NHS organ donation register .....	16
4.2 Reasons for refusal for consent .....	16
4.3 Improving rates of identification and referral of potential donors .....	17
4.4 Improving consent rates .....	17
4.5 The experience of consenting for organ donation.....	17
5 Other versions of this guideline .....	19
5.1 Full guideline .....	19
5.2 Information for the public.....	19
6 Updating the guideline.....	20
Appendix A The Guideline Development Group, Short Clinical Guidelines Technical Team and NICE project team .....	21
The Guideline Development Group .....	21
The short clinical guidelines technical team.....	22

---

NICE project team .....	23
Appendix B The Guideline Review Panel.....	24
About this guideline .....	25

---

## Introduction

A significant proportion of people in England and Wales would wish to donate their organs after death for the purpose of transplantation. This guideline recognises the complexities that arise owing to the majority of potential organ donors lacking the capacity to be directly involved in decision making at the time of their death. This guideline seeks to promote the identification and fulfilment of these wishes through:

- more effective and expedient identification and referral of potential organ donors
- a more informed, considered and timely approach to consent for donation that is based primarily on identifying the wishes of the individual whenever known and however recorded.

The General Medical Council (GMC) guidance '[Treatment and care towards the end of life: good practice in decision making](#)' requires that consultant staff who have clinical responsibility for patients who are potential donors exercise a duty to consider organ donation as part of end-of-life care.

Although donation occurs after death, there are steps that healthcare professionals may need to take before the death of the patient if donation is to take place. This guidance covers such steps, and in the case of clinical triggers for referral, refers to actions that might take place even before the inevitability of death has been recognised. These actions may result in challenges and tensions for the healthcare teams but they can and indeed should be incorporated into local hospital policies in order to better promote donation as part of end-of-life care.

Organ donation for transplantation is a complex area and one to which conventional clinical research methods cannot be easily applied. Consequently, much of the evidence included in this guideline is of a qualitative nature and does not lend itself to conventional use of GRADE assessment. A modified version of the GRADE assessment tool has been used to assess study limitations, indirectness and inconsistency.

Recognising the ethical and legal context in this area, legal advice was sought and incorporated during the development of the guideline.

---

## Person-centred care

This guideline offers best practice advice on improving donor identification and consent rates.

Treatment and care should take into account people's needs and preferences. Where the person at the end of their life has the capacity to make decisions, they should have the opportunity to make informed decisions about their care, in partnership with their healthcare professionals. In many cases parents, families and guardians are an important part of the consent process and, unless the person has expressed otherwise, should be involved in decisions about consent. If potential donors do not have the capacity to make decisions, healthcare professionals should follow the Department of Health's [advice on consent](#) and the [code of practice that accompanies the Mental Capacity Act](#). In Wales, healthcare professionals should follow [advice on consent](#) from the Welsh Government.

If the potential donor is under 16, healthcare professionals should follow the guidelines in '[Seeking consent: working with children](#)'.

The Human Tissue Authority has produced [codes of practice for consent and for donation of solid organs for transplantation](#), and the NHS has produced a code of practice on confidentiality<sup>[1]</sup>.

Good communication between healthcare professionals and people is essential. It should be supported by evidence-based written information tailored to the person's needs. The information people are given about their care should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English.

Parents, families and guardians should also be given the information and support they need.

---

<sup>[1]</sup> NHS UK Transplant has produced a [policy on care of the donor family, and standards of practice for donor transplant coordinators](#).

## 1 Recommendations

### *Identifying patients who are potential donors*

- 1.1.1 Organ donation should be considered as a usual part of 'end-of-life care' planning.
- 1.1.2 Identify all patients who are potentially suitable donors as early as possible, through a systematic approach. While recognising that clinical situations vary identification should be based on either of the following criteria:
- defined clinical trigger factors in patients<sup>[2]</sup> who have had a catastrophic brain injury, namely:
    - the absence of one or more cranial nerve reflexes **and**
    - a Glasgow Coma Scale (GCS) score of 4 or less that is not explained by sedation

unless there is a clear reason why the above clinical triggers are not met (for example because of sedation) and/or a decision has been made to perform brainstem death tests, whichever is the earlier

- the intention to withdraw life-sustaining treatment in patients with a life-threatening or life-limiting condition which will, or is expected to, result in circulatory death.
- 1.1.3 The healthcare team caring for the patient should initiate discussions about potential organ donation with the specialist nurse for organ donation at the time the criteria in recommendation 1.1.2 are met.

### *Patients who have capacity*

- 1.1.4 In circumstances where a patient has the capacity to make their own decisions, obtain their views on, and consent to, organ donation<sup>[3]</sup>.

---

## ***Assessing best interests***

- 1.1.5 If a patient lacks capacity to make decisions about their end-of life-care, seek to establish whether taking steps, before death, to facilitate organ donation would be in the best interests of the patient.
- 1.1.6 While assessing the patient's best interests clinically stabilise the patient in an appropriate critical care setting while the assessment for donation is performed – for example, an adult intensive care unit or in discussion with a regional paediatric intensive care unit (see recommendation 1.1.8).
- 1.1.7 Provided that delay is in the patient's overall best interests, life-sustaining treatments should not be withdrawn or limited until the patient's wishes around organ donation have been explored and the clinical potential for the patient to donate has been assessed in accordance with [legal](#) and professional<sup>[4],[5]</sup> guidance.
- 1.1.8 In assessing a patient's best interests, consider:
- the patient's known wishes and feelings, in particular any advance statement or registration on the NHS organ donor register<sup>[6]</sup> but also any views expressed by the patient to those close to the patient
  - the beliefs or values that would be likely to influence the patient's decision if they had the capacity to make it
  - any other factors they would be likely to consider if they were able to do so
  - the views of the patient's family, friends and anyone involved in their care as appropriate as to what would be in the patient's best interests; and
  - anyone named by the patient to be consulted about such decisions.

## ***Seeking consent to organ donation***

- 1.1.9 If a patient lacks the capacity to consent to organ donation seek to establish the patient's prior consent by:

- referring to an advance statement if available
- establishing whether the patient has registered and recorded their consent to donate on the NHS organ donor register<sup>[6]</sup> and
- exploring with those close to the patient whether the patient had expressed any views about organ donation.

1.1.10 If the patient's prior consent has not already been ascertained, and in the absence of a person or persons having been appointed as nominated representative(s), consent for organ donation should be sought from those in a qualifying relationship with the patient. Where a nominated representative has been appointed and the person had not already made a decision about donation prior to their death, then consent should be sought after death from the said nominated representative(s).

## ***Approach to those close to the patient***

### **The multidisciplinary team**

1.1.11 A multidisciplinary team (MDT) should be responsible for planning the approach and discussing organ donation with those close to the patient.

1.1.12 The MDT should include:

- the medical and nursing staff involved in the care of the patient, led throughout the process by an identifiable consultant
- the specialist nurse for organ donation
- local faith representative(s) where relevant.

1.1.13 Whenever possible, continuity of care should be provided by team members who have been directly involved in caring for the patient.

1.1.14 The MDT involved in the initial approach should have the necessary skills and knowledge to provide to those close to the patient appropriate support and



---

accurate information about organ donation (see [recommendations 1.1.30 and 1.1.31](#)).

## ***Discussions in all cases***

1.1.15 Before approaching those close to the patient:

- identify a patient's potential for donation in consultation with the specialist nurse for organ donation
- check the NHS organ donor register and any advance statements or Lasting Power of Attorney for health and welfare
- clarify coronial, legal and safeguarding issues.

1.1.16 Before approaching those close to the patient, try to seek information on all of the following:

- knowledge of the clinical history of the patient who is a potential donor
- identification of key family members
- assessment of whether family support is required – for example faith representative, family liaison officer, bereavement service, trained interpreter, advocate
- identification of other key family issues
- identification of cultural and religious issues that may have an impact on consent.

1.1.17 Approach those close to the patient in a setting suitable for private and compassionate discussion.

1.1.18 Every approach to those close to the patient should be planned with the MDT and at a time that suits the family's circumstances.

1.1.19 In all cases those close to the patient should be approached in a professional, compassionate and caring manner and given sufficient time to consider the information.

1.1.20 Discussions about organ donation with those close to the patient should only take place when it has been clearly established that they understand that death is inevitable or has occurred.

1.1.21 When approaching those close to the patient:

- discuss with them that donation is a usual part of the end-of-life care
- use open-ended questions – for example 'how do you think your relative would feel about organ donation?'
- use positive ways to describe organ donation, especially when patients are on the NHS organ donor register or they have expressed a wish to donate during their lifetime – for example 'by becoming a donor your relative has a chance to save and transform the lives of many others'
- avoid the use of apologetic or negative language (for example 'I am asking you because it is policy' or 'I am sorry to have to ask you').

1.1.22 The healthcare team providing care for the patient should provide those close to the patient who is a potential donor with the following, as appropriate:

- assurance that the primary focus is on the care and dignity of the patient (whether the donation occurs or not)
- explicit confirmation and reassurance that the standard of care received will be the same whether they consider giving consent for organ donation or not
- the rationale behind the decision to withdraw or withhold life-sustaining treatment and how the timing will be coordinated to support organ donation
- a clear explanation of, and information on:
  - the process of organ donation and retrieval, including post-retrieval arrangements
  - what interventions may be required between consent and organ retrieval
  - where and when organ retrieval is likely to occur

- 
- how current legislation applies to their situation<sup>[7]</sup>, including the status of being on the NHS organ donor register or any advance statement
  - how the requirements for coronial referral apply to their situation
- consent documentation
  - reasons why organ donation may not take place, even if consent is granted.
- 1.1.23 Allow sufficient time for those close to the patient to understand the inevitability of the death or anticipated death and to spend time with the patient.
- 1.1.24 Discuss withdrawal of life-sustaining treatment or neurological death before, and at a different time from, discussing organ donation unless those close to the patient initiate these discussions in the same conversation.
- 1.1.25 For discussions where circulatory death is anticipated, provide a clear explanation on:
- what end-of-life care involves and where it will take place – for example, theatre, critical care department
  - how death is confirmed and what happens next
  - what happens if death does not occur within a defined time period.
- 1.1.26 For discussions where neurological death is anticipated, provide a clear explanation on:
- how death is diagnosed using neurological criteria
  - how this is confirmed and what happens next.

## ***Organisation of the identification, referral and consent processes***

- 1.1.27 Each hospital should have a policy and protocol that is consistent with these recommendations for identifying patients who are potential donors and managing the consent process.

- 
- 1.1.28 Each hospital should identify a clinical team to ensure the development, implementation and regular review of their policies.
- 1.1.29 Adult and paediatric intensive care units should have a named lead consultant with responsibility for organ donation.
- 1.1.30 The MDT involved in the identification, referral to specialist nurse for organ donation, and consent should have the specialist skills and competencies necessary to deliver the recommended process for organ donation outlined in this guideline.
- 1.1.31 The skills and competencies required of the individual members of the team will depend on their role in the process. However, all healthcare professionals involved in identification, referral to specialist nurse for organ donation, and consent processes should:
- have knowledge of the basic principles and the relative benefits of, donation after circulatory death (DCD) versus donation after brainstem death (DBD)
  - understand the principles of the diagnosis of death using neurological or cardiorespiratory criteria and how this relates to the organ donation process
  - be able to explain neurological death clearly to families
  - understand the use of clinical triggers to identify patients who may be potential organ donors
  - understand the processes, policies and protocols relating to donor management
  - adhere to relevant professional standards of practice regarding organ donation and end-of-life care.
- 1.1.32 Consultant staff should have specific knowledge and skills in:
- the law surrounding organ donation
  - medical ethics as applied to organ donation

- the diagnosis and confirmation of death using neurological or cardiorespiratory criteria
- the greater potential for transplantation of organs retrieved from DBD donors compared with organs from DCD donors
- legally and ethically appropriate clinical techniques to secure physiological optimisation in patients who are potential organ donors
- communication skills and knowledge necessary to improve consent ratios for organ donation.

---

<sup>[2]</sup> It is recognised that a proportion of the patients who are identified by these clinical triggers will survive.

<sup>[3]</sup> If the potential donor is under 16, healthcare professionals should follow the guidelines in '[Seeking consent: working with children](#)'

<sup>[4]</sup> DCD consensus meeting report, available from [www.ics.ac.uk/intensive\\_care\\_professional/standards\\_and\\_guidelines/dcd](http://www.ics.ac.uk/intensive_care_professional/standards_and_guidelines/dcd)

<sup>[5]</sup> [GMC guidance on treatment and care towards the end of life](#)

<sup>[6]</sup> Available from [www.uktransplant.org.uk](http://www.uktransplant.org.uk) or [www.organdonation.nhs.uk](http://www.organdonation.nhs.uk)

<sup>[7]</sup> Mental Capacity Act (2005) and Human Tissue Act (2004).

---

## 2 Notes on the scope of the guideline

NICE guidelines are developed in accordance with a scope that defines what the guideline will and will not cover. The [scope](#) of this guideline is available.

---

## 3 Implementation

NICE has developed [tools](#) to help organisations implement this guidance.

---

## 4 Research recommendations

We have made the following recommendations for research, based on our review of evidence, to improve NICE guidance and patient care in the future.

### ***4.1 Joining the NHS organ donation register***

What are the factors and processes that would encourage the general public to sign up on the UK NHS organ donor register (ODR)?

#### **Why this is important**

Ninety percent of the UK general public approve of organ donation, but only 28% have registered on the ODR. Research is urgently needed to find out what factors would encourage people to register, and what processes could increase registration. If these factors could be identified and processes implemented, the number of people on the ODR could be significantly increased. Therefore the supply of donor organs should be improved given that evidence shows that families are more likely to consent if the potential donor is known to be on the ODR.

### ***4.2 Reasons for refusal for consent***

Why do families refuse to give permission for organ donation?

#### **Why this is important**

High-quality research using mixed methodology is needed to identify the reasons behind family refusal to see if there are factors that are changeable (for example, poor understanding of the process, medical mistrust, 'knee-jerk' response that is later regretted). The study could be, for example, a multi-centre observational study where all family members (those that did and those that did not give permission for their deceased loved one's organ donation) are followed up 6 months later.

Such research could determine whether those participants who gave permission for donation have higher perceived benefits scores, lower prolonged grief scores and higher quality-of-life scores than those who did not.



---

### ***4.3 Improving rates of identification and referral of potential donors***

What are the key components of an intervention to improve identification and referral rates?

#### **Why this is important**

Currently, the evidence for improving identification and referral rates consists mainly of observational reports of complex interventions, with most studies being of limited follow-up. Further research is needed to identify the components, or combinations of components, of the interventions that are effective in increasing identification and referral rates. These studies should have an appropriate length of follow-up to ensure a sustained impact in the longer term.

### ***4.4 Improving consent rates***

What are the key components of an intervention to improve consent rates?

#### **Why this is important**

Currently, the evidence for improving consent rates consists mainly of observational reports of complex interventions, with most studies being of limited follow-up. Further research is needed to identify the components, or combinations of components, of the identified interventions that are effective in increasing consent rates. These studies should have an appropriate length of follow-up to ensure a sustained impact in the longer term.

### ***4.5 The experience of consenting for organ donation***

Does a positive experience of approach and process of consent for families increase consent rates?

#### **Why this is important**

It is generally accepted that if families have a more positive experience of the approach and process of consenting, then rates of consent will increase. However, no high-quality evidence was identified to support this perception. Further research is needed to confirm this assumption

---

and, if true, to identify those components of the approach and process that are key to improving the experience, and hence the consent rate.

---

## 5 Other versions of this guideline

### ***5.1 Full guideline***

The full guideline, [Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation](#) contains details of the methods and evidence used to develop the guideline.

### ***5.2 Information for the public***

NICE has produced [information for the public](#) explaining this guideline.

We encourage NHS and voluntary sector organisations to use text from this information in their own materials about organ donation.

---

## 6 Updating the guideline

NICE clinical guidelines are updated so that recommendations take into account important new information. New evidence is checked 3 years after publication, and healthcare professionals and patients are asked for their views; we use this information to decide whether all or part of a guideline needs updating. If important new evidence is published at other times, we may decide to do a more rapid update of some recommendations. Please see [our website](#) for information about updating the guideline.

---

## **Appendix A The Guideline Development Group, Short Clinical Guidelines Technical Team and NICE project team**

### ***The Guideline Development Group***

**Tim Collins**

Intensive Care Unit Clinical Nurse Educator, Maidstone & Tunbridge Wells NHS Trust

**James Fraser**

Consultant in Paediatric Intensive Care, Bristol Royal Hospital for Children

**Gary McVeigh (Chair)**

Professor of Cardiovascular Medicine, Queen's University Belfast

**Karen Morgan**

Regional Manager, Organ Donation and Transplantation, NHS Blood and Transplant, Watford

**Paul Murphy**

Consultant in Neuroanaesthesia and Critical Care, The Leeds Teaching Hospitals NHS Trust

**Jane Nix**

Patient and carer member

**Ronan O'Carroll**

Professor of Psychology, University of Stirling

**Gurch Randhawa**

Professor of Diversity in Public Health and Director, University of Bedfordshire, Bedford

**Angus Vincent**

Consultant in Intensive Care Medicine and Anaesthesia, Newcastle upon Tyne Hospitals NHS Foundation Trust

**Huw Twamley**

Consultant in Critical Care and Anaesthesia, Lancashire Teaching Hospitals NHS Foundation Trust, Preston

---

**Barry Williams**

Patient and carer member

**Co-opted member**

The following person was not a full member of the Guideline Development Group but was co-opted onto the group as an expert adviser:

**Simon Bramhall**

Consultant Surgeon, Queen Elizabeth Hospital, Birmingham

***The short clinical guidelines technical team***

A short clinical guidelines technical team was responsible for this guideline throughout its development. It prepared information for the Guideline Development Group, drafted the guideline and responded to consultation comments. The following NICE employees made up the technical team for this guideline.

**Mark Baker**

Consultant Clinical Adviser

**Nicole Elliott**

Associate Director

**Michael Heath**

Programme Manager

**Kathryn Chamberlain**

Project Manager

**Hanna Lewin**

Information Specialist

**Prashanth Kandaswamy**

Senior Technical Adviser (Health Economics)

---

**Beth Shaw**

Senior Technical Adviser

**Faisal Siddiqui**

Technical Analyst

**Sheryl Warttig**

Technical Analyst

***NICE project team***

**Judith Richardson**

Associate Director

**Rachel Ryle**

Guideline Commissioning Manager

**Emma Banks**

Guideline Coordinator

**Ruaraidh Hill**

Technical Lead

**Stefanie Reken**

Health Economist

**Annette Mead**

Senior Medical Editor

---

## Appendix B The Guideline Review Panel

The Guideline Review Panel is an independent panel that oversees the development of the guideline and takes responsibility for monitoring adherence to NICE guideline development processes. In particular, the panel ensures that stakeholder comments have been adequately considered and responded to. The panel includes members from the following perspectives: primary care, secondary care, lay, public health and industry.

### **Mike Drummond (Chair)**

Director, Centre for Health Economics, University of York

### **Ailsa Donnelly**

Patient and carer member

### **Sarah Fishburn**

Patient and carer member

### **John Harley**

Clinical Governance and Prescribing Lead and General Practitioner, North Tees PCT

### **Ruth Stephenson**

Consultant in Anaesthetics Clinical Ethics Lead, NHS Grampian



---

## About this guideline

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.

The guideline was developed by the Centre for Clinical Practice at NICE, which worked with a group of healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation.

The methods and processes for developing NICE clinical guidelines are described in [The guidelines manual](#). This guideline was developed using the [short clinical guideline process](#).

The recommendations from this guideline have been incorporated into a [NICE Pathway](#). We have produced [information for the public](#) explaining this guideline. Tools to help you put the guideline into practice and information about the evidence it is based on are also [available](#).

### Changes after publication

**November 2012:** minor maintenance

### Your responsibility

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

### Copyright

---

© National Institute for Health and Clinical Excellence 2011. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

### **Contact NICE**

National Institute for Health and Clinical Excellence  
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT  
[www.nice.org.uk](http://www.nice.org.uk)  
[nice@nice.org.uk](mailto:nice@nice.org.uk)  
0845 033 7780